FattyLiverAlliance on Twitter
Stephen Harrison presenting this morning at #easlcongress on “Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibro-inflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-Week Multicenter, Randomized,… pic.twitter.com/GXV5WoRzpM— FattyLiverAlliance (@FattyLiverA) June 23, 2023
https://twitter.com/FattyLiverA/status/1672144869886685189